Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to Neutral at Cantor Fitzgerald

Cantor Fitzgerald cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from an overweight rating to a neutral rating in a research report report published on Wednesday morning, Marketbeat.com reports. Cantor Fitzgerald currently has $36.00 target price on the specialty pharmaceutical company’s stock, down from their prior target price of $57.00.

Supernus Pharmaceuticals Stock Down 4.5 %

NASDAQ SUPN opened at $33.05 on Wednesday. Supernus Pharmaceuticals has a 12-month low of $25.53 and a 12-month high of $40.28. The company has a market capitalization of $1.83 billion, a PE ratio of 30.89 and a beta of 0.90. The firm’s 50 day moving average is $37.48 and its 200-day moving average is $35.30.

Insider Activity

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the transaction, the vice president now directly owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in SUPN. Pacer Advisors Inc. grew its stake in shares of Supernus Pharmaceuticals by 29.9% in the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock valued at $54,655,000 after buying an additional 403,028 shares in the last quarter. Woodline Partners LP grew its stake in shares of Supernus Pharmaceuticals by 124.8% in the fourth quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company’s stock valued at $15,326,000 after buying an additional 235,257 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Supernus Pharmaceuticals by 248.0% in the fourth quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company’s stock valued at $10,581,000 after buying an additional 208,552 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at $6,847,000. Finally, Great Lakes Advisors LLC bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at $6,131,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.